{
    "nct_id": "NCT05867121",
    "official_title": "A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy at least 3 months\n* Adequate hematologic and end organ function\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy\n* Measurable disease according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) images within 28 days prior to enrollment\n* Availability of representative tumor specimens in formalin-fixed, paraffin-embedded (FFPE) blocks or at least 15 unstained slides\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or breastfeeding, or intending to become pregnant during the study or within 9 months after the final dose of oxaliplatin and within 6 months after the final dose of all other study treatment\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Positive test for human immunodeficiency virus (HIV) infection\n* Positive hepatitis B surface antigen (HbsAg) test, and/or positive total hepatitis B core antibody (HbcAb) test at screening\n* Positive hepatitis C virus (HCV) antibody test at screening\n* Known allergy or hypersensitivity to any component of the RO7496353 formulation or any of the study drugs or their excipients\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}